########################################
# Program: needle
# Rundate: Wed 30 May 2018 14:54:41
# Commandline: needle
#    -outfile /Users/teresatavella/Documents/models_new/seqid30_85/gb_CCE36834_ARO_3003784_Mycobacterium_6cn1_F/needle.txt
#    -asequence /Users/teresatavella/Documents/models_new/seqid30_85/gb_CCE36834_ARO_3003784_Mycobacterium_6cn1_F/gb_CCE36834_ARO_3003784_Mycobacterium_tuberculosis_intrinsic_murA_conferring_resistance_to_fosfomycin__Mycobacterium_tuberculosis_UT205.fa
#    -bsequence /Users/teresatavella/Documents/models_new/seqid30_85/gb_CCE36834_ARO_3003784_Mycobacterium_6cn1_F/6cn1_F.fa
#    -gapopen 10
#    -gapextend 0.5
# Align_format: srspair
# Report_file: /Users/teresatavella/Documents/models_new/seqid30_85/gb_CCE36834_ARO_3003784_Mycobacterium_6cn1_F/needle.txt
########################################

#=======================================
#
# Aligned_sequences: 2
# 1: gb_CCE36834_ARO_3003784_Mycobacterium_tuberculosis_intrinsic_murA_conferring_resistance_to_fosfomycin__Mycobacterium_tuberculosis_UT205
# 2: 6cn1_F_mol_protein_length_424__UDP-N-acetylglucosamine_1-carboxyvinyltransferase
# Matrix: EBLOSUM62
# Gap_penalty: 10.0
# Extend_penalty: 0.5
#
# Length: 430
# Identity:     190/430 (44.2%)
# Similarity:   266/430 (61.9%)
# Gaps:          21/430 ( 4.9%)
# Score: 895.5
# 
#
#=======================================

gb_CCE36834_A      1 MAERFVVTGGNRLSGEVAVGGAKNSVLKLMAATLLAEGTSTITNCPDILD     50
                      .::.::|||.||.||:.:.||||:.|.::||||||:|..|:.|.|.:.|
6cn1_F_mol_pr      1 -MDKLIITGGARLDGEIRISGAKNAALPILAATLLADGPVTVGNLPHLHD     49

gb_CCE36834_A     51 VPLMAEVLRGLG--------ATVELD-GDVARITAPDEPKYDADFAAVRQ     91
                     :..|.|:...:|        .:||:| ..:..:.||        :..|:.
6cn1_F_mol_pr     50 ITTMIELFGRMGIEPVIDEKLSVEIDPRTIKTLVAP--------YELVKT     91

gb_CCE36834_A     92 FRASVCVLGPLVGRCKRARVALPGGDAIGSRPLDMHQAGLRQLGAHCNIE    141
                     .|||:.||||:|.|...|.||||||.||||||:|:|..||..:||...:|
6cn1_F_mol_pr     92 MRASILVLGPMVARFGEAEVALPGGCAIGSRPVDLHIRGLEAMGAKIEVE    141

gb_CCE36834_A    142 HGCVVARAET--LRGAEIQLEFPSVGATENILMAAVVAEGVTTIHNAARE    189
                     .|.:.|:|..  ||||....:..||..||||:|||.:|:|.:.:.|||||
6cn1_F_mol_pr    142 GGYIKAKAPEGGLRGAHFFFDTVSVTGTENIMMAAALAKGRSVLQNAARE    191

gb_CCE36834_A    190 PDVVDLCTMLNQMGAQVEGAGSPTMTITGVPRLHPTEHRVIGDRIVAATW    239
                     |:||||...:|.||..::|||:.|:||.||.||....:||:.|||...|:
6cn1_F_mol_pr    192 PEVVDLANFINAMGGNIQGAGTDTITIDGVERLDSANYRVMPDRIETGTY    241

gb_CCE36834_A    240 GIAAAMTRGDISVAGVDPAHLQLVLHKLHDAGATVTQTDASFRVTQY-ER    288
                     .:|||:|.|.:.|...||..|:.||.||.:|||.:...:....:..: :|
6cn1_F_mol_pr    242 LVAAAVTGGRVKVKDTDPTILEAVLEKLKEAGADINTGEDWIELDMHGKR    291

gb_CCE36834_A    289 PKAVNVATLPFPGFPTDLQPMAIALASIADGTSMITENVFEARFRFVEEM    338
                     |||||:.|.|:|.||||:|...|:|.:||:||..:.|.:||.||..|.||
6cn1_F_mol_pr    292 PKAVNLRTAPYPAFPTDMQAQFISLNAIAEGTGAVIETIFENRFMHVYEM    341

gb_CCE36834_A    339 IRLGADARTDGHHAVVRGLPQLSSAPVWCSDIRAGAGLVLAGLVADGDTE    388
                     .|:||..:.:|:.|:|.|:..|..|||..:|:||.|.|||:.|||:|||.
6cn1_F_mol_pr    342 HRMGAQIQVEGNTAIVTGVKALKGAPVMATDLRASASLVLSALVAEGDTL    391

gb_CCE36834_A    389 VHDVFHIDRGYPLFVENLVSLGAEIERVCC    418
                     :..::||||||....|.|..|||:|.||..
6cn1_F_mol_pr    392 IDRIYHIDRGYECIEEKLQMLGAKIRRVPG    421


#---------------------------------------
#---------------------------------------